anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Aluminum phosphide (AlP) is a chemical compound that can cause death in some countries. AlP inhibits the functioning of cytochrome C oxidase in the mitochondria of cardiomyocytes, leading to toxicity. Oxidative stress and ROS production, as well as inflammatory signaling, mediate the mechanisms of AlP-related toxicity in the poisoned patient. Unfortunately, there are no approved medicines available to treat AlP poisoning yet. To address this issue, researchers have explored various interventions to reduce the toxicity associated with AlP tablets.
METHODS: We systematically searched relevant databases for English articles published between 2013 and 2024.
RESULTS: The evaluated treatments included correcting oxidative stress parameters, enhancing exogenous antioxidant capacity, modifying electrocardiographic abnormalities, and improving heart contraction strength. Our evaluation indicated that compounds like Triiodothyronine, Vasopressin and milrinone, Iron sucrose, Acetyl-l-carnitine, Melatonin, Fresh red blood cell transfusion, Minocycline, Moringa oleifera extract, Dihydroxyacetone, Selegiline, Nanocurcumin, Levosimendan, Exenatide, Taurine, Cannabidiol and Edaravone are effective in lessening AlP-induced cardiotoxicity.
CONCLUSION: Based on the present study's findings and the evaluation of clinical studies, dihydroxyacetone, fresh red blood cell infusion, Oil-based disinfection, and gastric lavage have the most potential to save patients' lives and treat acute aluminum phosphide. However, there is a need for more research in this regard.
BACKGROUND: Back pain is a typical condition, and the association among sleep disorders, sleep duration and back pain is currently being investigated. The purpose of this research is to explore the connection between sleep disorders, sleep duration and chronic back pain as well as confounding factors.
METHODS: Our data were obtained from the National Health and Nutrition Examination Survey (NHANES) data set of the USA and 1,131 participants were included in the study. Multivariable logistic regression was employed to investigate the relationship between sleep disorders, sleep duration and chronic back pain. And subgroup analysis conducted by gender, age, race, education, marital status, PIR, BMI, awakening events, hypertension condition and diabetes condition was also performed.
RESULTS: Our study includes 1131 participants, 513 are men (45.4%) and 618 are women (54.6%), 151 participants with sleep disorders (13.4%) and 980 participants without (86.6%). The fully adjusted model with adjustment variables including age, gender, race, BMI, PIR, drink, smoke, education, marital status, awakening conditions, hypertension, diabetes and part of back pain constructed through multiple logistic regression shows that chronic back pain is associated with sleep disorders [OR = 3.71, 95% CI: (1.25, 10.99), p < 0.05]. Using normal sleep duration as a reference, there is no statistical difference between short sleep duration [OR=-0.35, 95% CI: (-0.95, 0.24), p = 0.241], long sleep duration [OR = 0.81, 95% CI: (-1.61, 3.24), p = 0.513] and chronic back pain. It can be found through subgroup analysis that age between 40 and 60 years, age larger than 60 years, different race, marital status and BMI >30 kg/m2 are associated with chronic back pain and sleep disorders. We also find a nonlinear relation which is likely to be rotated S-shape among chronic back pain and sleep duration by fitting smooth curves.
CONCLUSION: Our results suggest a substantial positive relationship between chronic back pain and sleep disorders and there is no statistical association between sleep duration and chronic back pain. The findings drawn from our study provide a basis for future exploration of the causal association between chronic back pain and sleep disorders, and provide references for timely elimination of interfering factors.
The study is designed to evaluate the impact of telemonitoring on the follow-up of elderly patients with one or more chronic diseases among heart failure, chronic obstructive pulmonary disease and diabetes. The particular target of patients selected has the particularity of being "frail" according to a set of social eligibility criteria, agreed by the clinicians participating at the study. General practitioners are the first clinicians in charge of managing these patients during the trial follow-up. The term of comparison is represented by a control group, followed by outpatient usual care.

From a clinical point of view, the trial will investigate how the remote monitoring of some clinical parameters contributes to reduce the access to healthcare facilities (emergency and planned hospitalization, bed-days, ER, specialist and GP visits), to improve the patients health-related quality of life and to reduce the anxiety about health conditions. A cost-effectiveness and cost-utility analysis will be carried out in order to determine if and how telemonitoring helps to limit the healthcare expenditure. The evaluation will deal also with organizational changes and task shift due to telemonitoring introduction and patients and professionals perception towards the service.
Three forms of peripheral vestibular disorders, each with its typical symptoms and clinical signs, can be differentiated functionally, anatomically and pathophysiologically: 1. inadequate unilateral paroxysmal stimulation or rarely inhibition of the peripheral vestibular system, e. g., BPPV, Menière's disease, vestibular paroxysmia or syndrome of the third mobile windows; 2. acute unilateral vestibulopathy leading to an acute vestibular tone imbalance manifesting as an acute peripheral vestibular syndrome; and 3. loss or impairment of function of the vestibular nerve and/or labyrinth: bilateral vestibulopathy. For all of these diseases, current diagnostic criteria by the Bárány-Society are available with a high clinical and scientific impact, also for clinical trials. The treatment depends on the underlying disease. It basically consists of 5 principles: 1. Explaining the symptoms and signs, pathophysiology, aetiology and treatment options to the patient; this is important for compliance, adherence and persistence. 2. Physical therapy: A) For BPPV specific liberatory maneuvers, depending on canal involved. Posterior canal: The new SémontPLUS maneuver is superior to the regular Sémont and Epley maneuvers; horizontal canal: the modified roll-maneuver; anterior canal the modified Yacovino-maneuver; 3. Symptomatic or causative drug therapy. There is still a deficit of placebo-controlled clinical trials so that the level of evidence for pharmacotherapy is most often low. 4. Surgery, mainly for the syndrome of the third mobile windows. 5. Psychotherapeutic measures for secondary functional dizziness.
1. The isolated strain of Penicillium oxalicum var. Armeniaca CCM 8242 used for obtaining the red colorant anthraquinone type. 2. A method for obtaining the red colorant anthraquinone type characterised in that the strain of Penicillium oxalicum var. Armeniaca CCM 8242 is cultivated at the temperature of 25 to 30 degree C, at a gauge pressure of 50 to 80 kPa (0.5 to 0.8 atm), in a broth of pH 3 to 9, containing carbohydrates and ammonia nitrogen, with continuous mixing at a peripheral speed of 280 rpm, with air supplied at a ratio of 1.2 volumes of air to 1.0 volume of a broth for 60 to 72 hours, and the red colorant thus produced is isolated from the nutrient broth. 3. The method according to Claim 2, characterised in that the cultivation is performed at the temperature of 27 to 29 degree C, for 64 to 68 hours, in a broth having pH 5.8 to 6.2, containing from 1.5 to 1.8 wt. % carbohydrates and from 0.66 to 0.69 wt. % ammonia nitrogen.
Provided are a facial mask pack product for administration of active agents to different areas of the skin and the use thereof for the facial treatment. Therefore, the product provides different active agents to different areas of the face which need diverse requirements for facial treatment. The facial mask pack product is characterized by comprising a first water-insoluble substrate and a second water-insoluble substrate, wherein the first water-insoluble substrate contains a first active agent while the second water-insoluble substrate does not contains the first active agent. The first water-insoluble substrate is applied to the forehead and the second water-insoluble substrate is applied to areas adjacent to lips. Both substrates contain about 50 wt.% of liquid carrier, based on the total weight thereof. The first water-insoluble substrate is selected from the group consisting of C2-C6 alcohol, cedrus atlantica bark extract and hamamelis virginiana extract, and the second water-insoluble substrate is selected from the group consisting of glycolic acid, salicylic acid, butylene glycol, job's teat extract and thymus serpillum extract.
Participants will engage in 4 virtual sessions with a physiotherapist, over a 3 week period. They will be prescribed an individual exercise program (based on assessment). Participants will complete the program 3x/week independently and diarize the exercise on provided documents. For participants living within Winnipeg, they will also diarize their accelerometer use/sleeping times during wear.
Participants will be asked to report to the laboratory at 7:00 am following an overnight fast. Upon arrival, a Teflon catheter will be inserted in an antecubital vein of one arm for arterialized blood sampling and a baseline blood sample will be drawn. Arterialized blood samples will be obtained by wrapping the subjects' forearm in a heating blanket (45 °C) for 10 min prior to each blood collection time point. A second Teflon catheter will be inserted in an antecubital vein of the opposite arm, and participants will receive a priming dose of L-\[ring- 13C6\]phenylalanine (2.0 µmol∙kg) prior to initiating a continuous infusion of L-\[ring-13C6\]phenylalanine (0.05 µmol∙kg∙min) (t=-240). The prime and continuous tracer infusion will be passed through a 0.2 μm filter. Blood will be collected every 1 hour and biopsies of the vastus lateralis will be collected at t=-180 and t=-15 min using a 5 mm Bergström needle (modified for manual suction) under 2% xylocaine local anesthesia for the measurement of postabsorptive muscle protein synthesis rates. The second biopsy (t=-15 min) will be used to determine baseline levels of phosphorylated and total proteins involved in nutrient sensing and muscle anabolic signaling. Subsequently, the participants will ingest 6 oz of fresh ground center cut pork loin. This cut of meat was selected due to its low lipid content (2.5-3%) and it is uniform in shape, size and composition. Along with the ingested pork, the participants will consume 300 mL of water. The water will be enriched to 5% with tracer according to the phenylalanine content of \~4% in the pork. This approach is required to minimize disturbances in isotopic steady state and provide appropriate conditions for the calculation of postprandial muscle protein synthesis rates. The time required to consume the pork will be recorded. The completion of the pork meal and water will mark the start of the postprandial phase (t=0). During this period, arterialized blood samples will be collected into evacuated chilled heparinized tubes at t=30, 60, 90, 120, 180, 240, and 300 min. Additional muscle biopsies will be collected at t=120 and 300 min of the experimental infusion for the measurement of postprandial muscle protein synthetic and muscle anabolic signaling protein responses. The muscle biopsy samples will be freed from any visible blood, fat, and connective tissue, rapidly frozen in liquid nitrogen and stored at -80˚C until analysis. Blood samples will be centrifuged at 1,000×g at 4˚C for 10 min and separated plasma will be transferred to 2.0 ml cryovials. The plasma samples will be stored at -20˚C until further analysis.
The Latarjet technique has proven reliable for the treatment of dislocations, with lower recurrence rates (5%) even in the presence of bone lesions. This technique allows a stable fixation of the graft, with 2 screws, and the dynamic effect of the conjoint tendon, the sling effect. However, several complications are described, such as neurological injuries, nonunion and graft resorption. Hamel et al, showed that vascularization of the coracoid graft is impaired during the course of Latarjet procedure. Together with the small thickness of the coracoid, it may justify its high rate of resorption.

The Eden-Hybinette surgery does not have the potential advantages of the sling effect. However, it allows a better restoration of the area of the glenoid, without the risks related to the coracoid osteotomy. All clinical studies about the different bone grafting techniques have a low quality. Furthermore, there is no comparative study of the techniques of Latarjet and Eden-Hybinette.
For 40 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 10 minutes of low-intensity (50% of the maximum repetitions) and 10 minutes of high-intensity (80% of the maximum repetitions) resistance exercises will be applied in the presence of a physiotherapist. resistance exercises; shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle group will be performed. At the end of each session, 5 minutes of stretching exercises will also be applied.
PROBLEM TO BE SOLVED: To obtain the subject composition useful for the prevention and treatment of diabetes or hepatic carcinoma by compounding a biologically obtainable oil or fat which contains a high concentration of arachidonic acid. SOLUTION: This composition contains an arachidonic acid-containing oil or fat, or further contains a docosahexaenoic acid-containing oil or fat or an oyster extract, as essential component. The arachidonic acid-containing oil or fat is obtained from a culture product produced by culturing an arachidonic acid producible microorganism (e.g. an arachidonic acid-producible microorganism belonging to the genus Mortierella) using glucose and a yeast extract, preferably in the presence of soybean oil, and the content of the arachidonic acid is >=2 wt.%, preferably 10-99 wt.%, based on the total of the oil or fat. Further, when docosahexaenoic acid is compounded, its compounding ratio is preferably 0.5-1.5 times the arachidonic acid by weight. A health food for the prevention and treatment of diabetes or hepatic carcinoma can be obtained by using the composition.
Background The adoption and sustainment of evidence-based practices (EBPs) is a challenge within many healthcare systems, especially in settings that have already strived but failed to achieve longer-term goals. The Veterans Affairs (VA) Maintaining Implementation through Dynamic Adaptations (MIDAS) Quality Enhancement Research Initiative (QUERI) program was funded as a series of trials to test multi-component implementation strategies to sustain optimal use of three EBPs: 1) a deprescribing approach intended to reduce potentially inappropriate polypharmacy; 2) appropriate dosing and drug selection of direct-acting anticoagulant medications (DOACs); and 3) use of cognitive behavioral therapy as first-line treatment for insomnia before pharmacologic treatment. We describe the design and methods for a harmonized series of cluster-randomized control trials comparing two implementation strategies.

Methods For each trial, we will recruit 8-12 clinics (24-36 total). All will have access to a clinical dashboard that flags patients who may benefit from the target EBP at that clinic and provider. For each trial, clinics will be randomized to one of two implementation strategies to improve use of the EBPs: 1) individual-level academic detailing (AD); or 2) AD plus the team-based Learn. Engage. Act. Process. (LEAP) quality improvement (QI) learning program. The primary outcomes will be operationalized across the three trials as a patient-level dichotomous response (yes/no) indicating patients with potentially inappropriate medications (PIMs) among those who may benefit from the EBP. This outcome will be computed using month-by-month administrative data. Primary comparison between the two implementation strategies will be analyzed using generalized estimating equations (GEE) with clinic-level monthly percent of PIMs as the dependent variable. Primary comparative endpoint will be at 13-18 months post-baseline. Each trial will also be analyzed independently.

Discussion MIDAS QUERI trials will focus on fostering sustained use of EBPs that previously had targeted but incomplete implementation. Our implementation approaches are designed to engage frontline clinicians in a dynamic optimization process that integrates use of actionable clinical dashboard data and making incremental changes, designed to be feasible within busy clinical settings.
The present invention provides biocompatible comb-type polymer molecules, comprising a hydrophilic backbone having branch-point moieties, and hydrophobic branches attached at these branch-point moieties. The invention provides aqueous suspensions of polymer aggregates formed from such polymers, and provides methods for solubilizing insoluble or sparingly-soluble organic compounds, such as drugs, dyes, vitamins, and the like, by incorporating such compounds in the hydrophobic cores of the polymer aggregates. The method for solubilizing a water-insoluble organic species in an aqueous solvent basically comprises contacting the water-insoluble organic species with a polymer of the invention in an aqueous or mixed-aqueous solvent. In particular embodiments, the branch point moieties further comprise reactive functional groups capable of serving as attachment points for targeting moieties. In particularly preferred embodiments, targeting moieties such as ligands or antibodies are covalently attached to the branch-point moieties of the polymers of the invention, and a drag is incorporated into the core of the aggregates, so as to form a targeted drug complex. The invention further provides methods for the preparation of the comb-type polymers, aggregates, and targeted drug complexes described herein. The polymers of the invention self- assemble into polymer aggregates that efficiently solubilize, distribute, and deliver drugs in vivo, are non-toxic and biocompatible, are stable, and are capable of bearing multiple cell targeting moieties on their exterior surfaces.
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is currently approved by the FDA for the treatment of multiple myeloma. Lenalidomide is approved for use with dexamethasone for patients with multiple myeloma who have received at least one prior therapy and for the treatment of certain types of myelodysplastic syndrome (another type of cancer affecting the blood). Dexamethasone is commonly used, either alone, or in combination with other drugs, to treat multiple myeloma. Please note that Bortezomib and Lenalidomide are provided to patients participating in this trial at no charge. Melphalan and cyclophosphamide, the drugs used during stem cell collection and transplant, are also approved by the FDA. Melphalan is an FDA-approved chemotherapy for multiple myeloma and is used as a high-dose conditioning treatment prior to stem cell transplantation. Cyclophosphamide is used, either alone, or in combination with other drugs, to treat multiple myeloma. These drugs have been used in other multiple myeloma studies and information from those studies suggests that this combination of therapy may help to treat newly diagnosed multiple myeloma.

After screening procedures determine if a patient is eligible for this research study, the patient will be randomized into one of the study groups: lenalidomide, bortezomib and dexamethasone without autologous stem cell transplantation, followed by lenalidomide maintenance (Arm A) or lenalidomide, bortezomib and dexamethasone with autologous stem cell transplantation, followed by lenalidomide maintenance (Arm B). There is an equal chance of being placed in either group. Randomization was stratified by International Staging System (ISS) disease stage (I, II, or III) and cytogenetics (high-risk \[presence of 17p deletion, t(4;14), or t(14;16) on fluorescence in-situ hybridization\], standard-risk \[absence of high-risk abnormalities\], or undetermined \[test failure\]) assessed locally in a screening bone marrow sample, with positivity cut-offs per institutional standards.
Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
The investigators used mixed methods to evaluate the implementation in two VA Women's Practice Based Research Network (PBRN) sites, describing services and patterns of care utilized by patients prior to seeing a care manager, and then 30, 60, 180, and 365 days post initiation of care with the care manager. Investigators also evaluated facilitators and barriers to implementation of this collaborative care model.
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy that has resulted in tremendous progress in the treatment of patients with B cell malignancies. However, significant toxicities may also be associated with such therapy. Here we report extremely high ferritin in a male patient after such therapy.
CASE PRESENTATION: We present a case of a 52 year old male with a history of B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell (CAR-T) therapy with rapcabtagene autoleucel (carvykti). The patient subsequently developed cytokine release syndrome (CRS) which during its resolution results in a hemophagocytic lymphohistiocytosis (HLH)-like syndrome that fell short of being diagnostic. This syndrome tracked closely with the onset and resolution of immune-effector cell-associated neurotoxicity syndrome (ICANS), with close correlation between the severity of laboratory abnormalities, particularly extremely high ferritin (peak value: 81,540 μg/L), and clinical encephalopathy.
CONCLUSIONS: Cytokine release syndrome after experimental (CAR) T cell therapy may cause extremely elevated ferritin and hemophagocytic lymphohistiocytosis -like syndrome.
E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.